Exit 156 Capital — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
NightWarenightware.cominApr 2026
NightWare is an FDA-cleared prescription digital therapeutic system designed to interrupt nightmares as they occur, improving sleep quality for patients with Nightmare Disorder, including those with PTSD.
Digital HealthHealthtechMedical DevicesMental HealthHopkins, US
Matthew Tucker(Executive Officer, Director)inGrady Hannah(Director)Michael Nathan(Executive Officer, Director)
BoardMichael Ott(Director)Gerald Mattys(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.